Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

Completed · Not applicable · Has a placebo group

Conditions studied: Age-Related Cognitive Decline, Age-Related Memory Disorders

In brief

The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline. DHA is a long chain omega-3 fatty acid (LC-PUFA) that plays an important role in neural and visual development and cardiovascular health.

Key facts

Study ID

NCT00278135

Run by

dsm-firmenich Switzerland AG

People needed

485

Starts

2005-12-01

Expected to finish

2008-12-01

Last updated by the study team

2014-05-19

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females, aged 55 or greater.
• Have a subjective memory complaint and have a Logical Memory subtest (of the Wechsler Memory Scale - III [WMS-III]) raw score one standard deviation or greater below the mean of a younger population.
• Have the ability to understand the requirements of the study; be willing to provide written informed consent; and agree to abide by the study restrictions and return for the required assessments.
• If taking non-prohibited medication, be on a stable drug regimen (in prior 3 months).

You may not qualify if…

• Have a screening Mini-Mental State Examination (MMSE) < 26.
• Consume greater than 200 mg/day DHA as assessed on a DHA Food Frequency Questionnaire in the prior 2 months to screening.
• Use nutritional fish oil, flaxseed oil, omega-3 supplements, or huperzine in the prior 2 months to screening.
• Use acetylcholinesterase inhibitors or memantine in the prior 2 months to screening.
• Use major anti-psychotics or major anti-depressants.
• Use lipase inhibitors such as Xenical® (orlistat).
• History of major medical conditions including ischemic stroke, head trauma with loss of consciousness, epilepsy, psychosis, vascular dementia, depression (Geriatric Depression [15-item] > 5), myocardial infarction (within 1 year), uncontrolled diabetes, or blindness.
• History of major surgery within the past 6 months.
• Current use or history of drug and/or alcohol abuse within 5 years.
• Administration of any investigational product within the past 30 days.
• Inability to swallow capsules.

Where it is running

• Pivotal Research Center — Mesa, Arizona, United States
• Pacific Research Network — San Diego, California, United States
• Pacific Research Network — Vista, California, United States
• Radiant Research Denver — Denver, Colorado, United States
• Bradenton Neurology — Bradenton, Florida, United States
• Brain Matters Research — Delray Beach, Florida, United States
• Meridien Research — St. Petersburg, Florida, United States
• Stedman Clinical Trials — Tampa, Florida, United States
• Radiant Research Chicago — Chicago, Illinois, United States
• Clinical Trial Center — Jenkintown, Pennsylvania, United States
• Senior Adults Specialty Research — Austin, Texas, United States
• Radiant Research San Antonio — San Antonio, Texas, United States
• Radiant Research Salt Lake City — Salt Lake City, Utah, United States
• Neurological Research Center, Inc. — Bennington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.